Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tebentafusp: First Approval
Sohita Dhillon
Drugs (2022) Vol. 82, Iss. 6, pp. 703-710
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 359
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 78
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Modulating T Cell Responses by Targeting CD3
Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1189-1189
Open Access | Times Cited: 41
Bioengineering of Antibody Fragments: Challenges and Opportunities
Sama Pirkalkhoran, Wiktoria Roksana Grabowska, Hamid Heidari Kashkoli, et al.
Bioengineering (2023) Vol. 10, Iss. 2, pp. 122-122
Open Access | Times Cited: 29
The potential and promise for clinical application of adoptive T cell therapy in cancer
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Melanoma biology and treatment: a review of novel regulated cell death-based approaches
Ming-yun Hsieh, Sheng‐Kai Hsu, Tzu‐Yu Liu, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 11
Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment
Tine Logghe, Eke van Zwol, Benoît Immordino, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 505-505
Open Access | Times Cited: 10
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial
Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese‐Bullock, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives
Tanmoy Kanp, Anish Dhuri, M Bharath, et al.
ACS Applied Bio Materials (2025)
Closed Access | Times Cited: 1
Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy
Jim Middelburg, Gaby Schaap, Marjolein Sluijter, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010331-e010331
Open Access | Times Cited: 1
Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM
Kei Saotome, Drew Dudgeon, Kiersten Colotti, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection
Kangping Yang, Yihan Zhang, Jiatong Ding, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 7
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab
Kouhei Tsumoto, Tsutomu Takeuchi
BioDrugs (2024) Vol. 38, Iss. 3, pp. 341-351
Open Access | Times Cited: 6
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
Junjun Liu, Jianwei Zhu
International Immunopharmacology (2024) Vol. 138, pp. 112609-112609
Closed Access | Times Cited: 6
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Timothy Qi, Xiaozhi Liao, Yanguang Cao
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 12, pp. 880-890
Open Access | Times Cited: 14
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Xue Ying, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Neoantigen cancer vaccines: a new star on the horizon
Xiaoling Li, Jian You, Liping Hong, et al.
Cancer Biology and Medicine (2023), pp. 1-38
Open Access | Times Cited: 13
1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature
Valentina Tonelotto, Marcel Costa-García, Eve O’Reilly, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
Jianting Long, Xihe Chen, Mian He, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors
Yuan Yuan, Junyan Li, Jie Chen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116565-116565
Open Access | Times Cited: 5
FDA Approvals of Biologics in 2022
Alexander C. Martins, Fernando Alberício, Beatriz G. de la Torre
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1434-1434
Open Access | Times Cited: 12
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Weihuan Shao, Yiran Yao, Ludi Yang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top